COPENHAGEN (Reuters) - Danish pharmaceutical group Lundbeck and Japanese partner Takeda said on Saturday that data from clinical phase III studies with the antidepressant vortioxetine had shown significant improvement in patients' symptoms. Lundbeck said in a statement that the trial showed safety levels consistent with previously completed studies at lower doses. Lundbeck and Takeda submitted vortioxetine, also known as Brintellix, for regulatory approval in the United States and Europe at the end of last year. ... Continue reading...
No comments:
Post a Comment